QTS Stock Chart & Stats
€183.80
€2.20(1.21%)
At close: 4:00 PM EDT
€183.80
€2.20(1.21%)
Day’s Range― - ―
52-Week Range€132.05 - €214.50
Previous CloseN/A
Volume17.00
Average Volume (3M)17.00
Market Cap
€34.91B
Enterprise Value€46.62K
Total Cash (Recent Filing)€2.08B
Total Debt (Recent Filing)€16.24B
Price to Earnings (P/E)29.9
Beta0.46
Next Earnings
Nov 04, 2026EPS Estimate
2.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.13
Shares Outstanding164,600,000
10 Day Avg. Volume5
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€236.89Price Target Upside28.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)11.25
Revenue Forecast (FY)€15.18B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationIQVIA generates consistently strong operating cash flow (~$2.1B–$2.9B annually) and reaccelerated free cash flow to $2.94B TTM with ~94% conversion. This durable cash generation supports debt service, buybacks, reinvestment in data/tech and cushions leverage risks over the medium term.
Robust Bookings And Backlog Providing Revenue VisibilityMaterial bookings growth and a large backlog (book-to-bill 1.22, $34.2B backlog, $9.23B next-12-month revenue) signal multi-period contract visibility. Strong demand for R&D services underpins predictable near-term revenue and supports durable top-line expansion across trial cycles.
AI-driven Differentiation And Client AdoptionWidespread deployment of AI agents and co-development with leading pharma firms creates a technology moat. AI improves trial efficiency, lowers operating costs, and strengthens client stickiness, supporting sustainable margin improvement and competitive advantage in tech-enabled CRO and data services.
Bears Say
Elevated Leverage And Large Gross Debt LoadIQVIA's high gross and net debt and elevated leverage materially reduce financial flexibility. Even with strong cash flow, ~3.6x net leverage and debt-to-equity near ~2.5 increase sensitivity to rate moves, constrain capital allocation choices and raise refinancing risk in adverse conditions.
Pass-through Revenue And FX Headwinds Compress MarginsRising pass-through revenues (no associated profit) structurally depress gross margins and inflate reported revenue, while volatile FX shifts reduce clarity on underlying performance. Together these recurring exposures limit sustainable margin expansion despite operational productivity gains.
Acquisition Mix Diluting Margin ProfileM&A is accelerating top-line growth but recent acquisitions have lower margins, which can dilute overall profitability. Reliance on inorganic growth increases integration and margin risk, making sustained margin improvement dependent on successful assimilation and cost synergies.
IQVIA Holdings News
QTS FAQ
What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest stock price was €132.05 and its highest was €214.50 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is €34.91B.
When is IQVIA Holdings’s upcoming earnings report date?
IQVIA Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 97 days.
How were IQVIA Holdings’s earnings last quarter?
IQVIA Holdings released its earnings results on Jul 28, 2026. The company reported €2.75 earnings per share for the quarter, beating the consensus estimate of €2.647 by €0.103.
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings does not currently pay dividends.
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate is 2.85.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 164,600,000 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
IQVIA Holdings reported an EPS of €2.75 in its last earnings report, beating expectations of €2.647. Following the earnings report the stock price went up 15.261%.
Which hedge fund is a major shareholder of IQVIA Holdings?
Currently, no hedge funds are holding shares in DE:QTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€236.89 (28.89% Upside)
€236.89 (28.89% Upside)
Blogger Sentiment
Neutral
DE:QTS Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.36%
Trailing 12-Months
Company Description
IQVIA Holdings
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
QTS Company Deck
QTS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall: the company beat Q2 guidance across revenue, adjusted EBITDA and adjusted EPS, reported accelerating organic growth and robust bookings momentum (notably a 19.3% YoY increase in quarterly R&DS bookings and a 1.22 book-to-bill). Management raised full-year revenue, EBITDA and EPS guidance and highlighted meaningful AI-driven wins and operational productivity gains. Headwinds include a reduced FX tailwind, pass-through revenue pressure, added leverage and some lower-margin acquisition contribution; management expects these non-operational items to offset some margin gains for the year. On balance, the highlights (revenue and earnings beats, strong bookings/backlog, FCF growth, AI traction and raised guidance) significantly outweigh the lowlights.View all DE:QTS earnings summariesQTS Revenue Breakdown
40.63% Technology & Analytics Solutions
54.54% Research & Development Solutions
4.83% Contract Sales & Medical Solutions
QTS Stock 12 Month Forecast
Average Price Target
€236.89
▲(28.89% Upside)